ClinicalTrials.gg

Program

ulotaront

Also written as “SEP-363856”, “SEP-363856 75mg” and “SEP363856”.

Its studies are mostly in Schizophrenia · Generalized Anxiety Disorder · Depressive Disorder, Major · Parkinson Disease · Narcolepsy, led by 2 companies.

Furthest: phase 3, since Aug 26, 201930 company-led studies, 5 open or runningNext primary completion: Mar 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka265 open or runningphase 3since Aug 26, 2019Oct 24, 2013Mar 2028phase 3 · NCT07225712
Sumitomo Pharma40 open or runningphase 3since Mar 29, 2021Nov 22, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Oct 24, 2013.

  1. Mar 29, 2021Phase 3 study in SchizophreniaSumitomo Pharma · NCT04825860 · 83 enrolled · China, Japan, Philippines and more
  2. Apr 26, 2021Phase 1 study in SchizophreniaOtsuka · NCT04865835 · 21 enrolled · United States
  3. Aug 10, 2021Phase 1 study in NarcolepsyOtsuka · NCT05015673 · 18 enrolled · United States
  4. Apr 27, 2022Phase 3 study in SchizophreniaSumitomo Pharma · NCT05359081 · 68 enrolled · Japan
  5. May 24, 2022Phase 1 study in SchizophreniaOtsuka · NCT05402111 · 31 enrolled · United States
  6. Jul 6, 2022Phase 1 study in SchizophreniaOtsuka · NCT05463770 · 15 enrolled · United States
  7. Aug 15, 2022Phase 1 study in SchizophreniaOtsuka · NCT05542264 · 19 enrolled · United States
  8. Oct 10, 2022Phase 2 study in Depressive Disorder, MajorOtsuka · NCT05593029 · 929 enrolled · United States, Bulgaria, Canada and more
  9. Nov 16, 2022Phase 3 study in SchizophreniaOtsuka · NCT05628103 · 101 enrolled · United States
  10. Feb 6, 20232 phase 3 studiesOtsuka · NCT05729373, NCT05741528
  11. Apr 27, 2023Phase 1 study in SchizophreniaOtsuka · NCT05848700 · 60 enrolled · United States
  12. Feb 27, 2025Phase 3 study in SchizophreniaOtsuka · NCT06894212 · 538 enrolled · United States, Japan
  13. Nov 5, 2025Phase 3 study in SchizophreniaOtsuka · NCT07225712 · 100 planned · Japan
  14. Aug 6, 20263 phase 3 studies in Generalized Anxiety DisorderOtsuka · NCT07759128, NCT07767903, NCT07786454

Ahead

  1. Mar 2028Primary completion: phase 3 study in SchizophreniaOtsuka · NCT07225712
  2. Oct 25, 2028Primary completion: phase 3 study in Generalized Anxiety DisorderOtsuka · NCT07767903
  3. Dec 6, 2028Primary completion: phase 3 study in Generalized Anxiety DisorderOtsuka · NCT07759128
  4. May 26, 2029Primary completion: phase 3 study in Generalized Anxiety DisorderOtsuka · NCT07786454

TargetBeta

HTR1A →TAAR1 →read by rule
“Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist”ChEMBL 37, by rule

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07786454Generalized Anxiety Disorder · United States3RecruitingOtsukaMay 26, 20291,120
NCT07767903Generalized Anxiety Disorder · United States3RecruitingOtsukaOct 25, 2028384
NCT07759128Generalized Anxiety Disorder · United States3RecruitingOtsukaDec 6, 2028576
NCT07225712Schizophrenia · Japan3RecruitingOtsukaMar 2028100
NCT06894212Schizophrenia · United States, Japan3Active, not recruitingOtsukaOct 20, 2026538
NCT05848700Schizophrenia · United States1CompletedOtsukaMar 15, 202460
NCT05741528Schizophrenia · United States3CompletedOtsukaSep 23, 202475
NCT05729373Generalized Anxiety Disorder · United States, Bulgaria, Estonia and more3CompletedOtsukaSep 26, 2025434
NCT05628103Schizophrenia · United States3CompletedOtsukaApr 1, 2024101
NCT05593029Depressive Disorder, Major · United States, Bulgaria, Canada and more2CompletedOtsukaNov 6, 2025929
NCT05542264Schizophrenia · United States1CompletedOtsukaFeb 12, 202419
NCT05463770Schizophrenia · United States1CompletedOtsukaAug 22, 202315
NCT05402111Schizophrenia · United States1CompletedOtsukaSep 27, 202331
NCT05359081Schizophrenia · Japan3TerminatedSumitomo PharmaMar 21, 202468
NCT05015673Narcolepsy · United States1CompletedOtsukaMay 26, 201518
NCT04865835Schizophrenia · United States1CompletedOtsukaMay 3, 202221
NCT04825860Schizophrenia · China, Japan, Philippines and more3TerminatedSumitomo PharmaOct 12, 202383
NCT04369391Schizophrenia · United States1CompletedOtsukaNov 10, 2020150
NCT04325737Schizophrenia · Japan1CompletedSumitomo PharmaAug 7, 202013
NCT04115319Schizophrenia · United States, Romania, Russia and more3CompletedOtsukaDec 30, 2022305
NCT04109950Schizophrenia · United States, Bulgaria, Colombia and more3TerminatedOtsukaNov 9, 2023463
NCT04092686Schizophrenia · United States, Bulgaria, Croatia and more3CompletedOtsukaJun 14, 2023464
NCT04072354Schizophrenia · United States, Bulgaria, Colombia and more3CompletedOtsukaMay 12, 2023463
NCT04038957Schizophrenia · United Kingdom1CompletedOtsukaJun 6, 202322
NCT03370640Schizophrenia · Japan1CompletedSumitomo PharmaSep 20, 201824
NCT02970929Schizophrenia · United States, Hungary, Romania and more2CompletedOtsukaJan 29, 2019157
NCT02969369Parkinson Disease Psychosis · United States2CompletedOtsukaApr 20, 202039
NCT02969382Schizophrenia · United States, Hungary, Romania and more2CompletedOtsukaJul 31, 2018245
NCT01994473Schizophrenia · United States1CompletedOtsukaDec 201448
NCT01972711Schizophrenia · United Kingdom1CompletedOtsukaJul 2015105

How it is read

Names in the registry

  • “SEP-363856”, 24 entries
  • “SEP-363856 75mg”, 2 entries
  • “SEP363856”, 2 entries
  • “SEP-363856 100mg”, 1 entry
  • “SEP-363856 50mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.